Starpharma Holdings Limited

Starpharma Holdings Limited is a biotechnology company specializing in the research, development, and commercialization of dendrimer technology, a class of synthetic nanoscale polymers with broad applications in healthcare. The company’s core purpose is to improve health outcomes for patients with serious illnesses, including cancer, through advanced drug delivery systems and anti-infective solutions. Notable innovations include the DEP® (dendrimer enhanced product) drug delivery platform, which optimizes the performance and safety of various pharmaceuticals, as well as marketed products like VivaGel® BV and VIRALEZE™ Nasal Spray, approved in multiple countries for infection prevention and treatment. Starpharma’s pipeline covers oncology, anti-infectives, and diagnostics, impacting sectors such as pharmaceuticals, medical devices, and life sciences. The business has built a reputation for partnering with global pharmaceutical companies to advance clinical trials and product commercialization. Its long-standing commitment to dendrimer technology positions Starpharma as a prominent leader in Australian biotech innovation, continually driving advancements aimed at meeting unmet medical needs and expanding global healthcare opportunities.